The independent pharmacy sector continues to evolve rapidly. Many owners are choosing to sell—whether to retire after decades in the business, consolidate with nearby competitors, or step away from intensifying reimbursement and operational pressures. At the same time, widespread closures, even among large chains, have created opportunities for buyers looking to expand their footprint or enter new markets.

A well-executed pharmacy transaction can be transformative, preserving community access to care while providing a strong return for the seller and a solid foundation for the buyer. However, these deals carry unique regulatory and compliance complexities. Oversights in due diligence, deal structuring, post-closing filings, or PBM recredentialing can lead to disrupted operations, unexpected liabilities, or significant financial losses long after the closing.

Below, we outline the most common—and costly—legal risks we see in pharmacy M&A, along with practical steps to mitigate them.

1. Inadequate Due Diligence: Inheriting Hidden Liabilities

Due diligence in pharmacy transactions goes far beyond reviewing financial statements and inventory counts. Buyers must uncover compliance and operational issues that could become their responsibility post-closing.

Key areas to examine thoroughly:

• PBM audits and disputes

  Open or prior audits, recoupments, network status, and any “at-risk” contract terms.

• Regulatory history

  DEA and state Board of Pharmacy inspections, complaints, disciplinary actions, or correspondence.

• Government program enrollment

  : Medicare/Medicaid provider status, PECOS updates, OIG exclusion checks, and any overpayment demands.

• Wholesaler and vendor agreements

  Exclusive purchasing obligations, credit terms, and potential termination rights.

• Licensure and permits

  Current status, renewal history, and any conditions or restrictions.

• Employment matters

  Independent contractor classifications, overtime exposure, and employee retention obligations.

• Third-party payer contracts

  Termination-for-convenience clauses and change-of-control provisions.

Why it matters: Undiscovered issues—such as an ongoing PBM audit or unresolved Board complaint—transfer to the buyer in ways that can threaten cash flow, licensure, or even viability.

Recommended approach: Engage experienced pharmacy counsel and consultants early to conduct targeted compliance due diligence. Use findings to negotiate price adjustments, escrow holdbacks, extended representations and warranties, or enhanced indemnification.

2. Flawed Deal Structure: Unintended Assumption of Liabilities

Most pharmacy acquisitions are structured as asset purchases to limit successor liability. However, that protection is only as strong as the documentation.

Critical drafting points:

• Explicitly list included assets (prescription files, inventory valued at cost, equipment, assignable contracts) and excluded assets/liabilities.

• Address prescription file transfer protocols, including patient notification and record retention.

• Handle real estate separately (lease assignment vs. new lease) to avoid personal guarantees carrying over.

• Clarify treatment of accounts receivable—buyers typically exclude pre-closing A/R to avoid inheriting audit risk.

Stock purchases, while simpler operationally, expose buyers to all historical liabilities, making robust due diligence and indemnification even more essential.

Recommended approach: Choose the structure that matches risk tolerance and negotiate clear schedules detailing exactly what transfers. Include survival periods for reps and warranties that align with common audit look-back periods (often 3–5 years).

3. Post-Closing Filing Deadlines: Avoiding Operational Shutdowns

The moment ownership changes, a series of mandatory notifications and applications begin—many with strict timelines.

Essential filings include:

• DEA

  Change of ownership notification or new registration (Schedule II–V authority cannot be operated under the seller’s registration post-closing).

• State Board of Pharmacy

  Change-of-ownership applications, which vary widely by state—some require advance approval.

• Medicare/Medicaid

  Form CMS-855B change of ownership (CHOW) or new enrollment, depending on structure.

• NCPDP/NPI updates

  To ensure claims route correctly.

• State controlled substance registration

  renewals or transfers.

Why it matters: Operating under the seller’s credentials after closing risks allegations of false claims or unlicensed practice. Delays can halt controlled substance dispensing or third-party reimbursements.

Recommended approach: Build a detailed post-closing compliance checklist with agency-specific deadlines well before closing. Assign responsibility and confirm receipt with each regulator.

4. PBM Recredentialing: Protecting Cash Flow

PBMs treat ownership changes as triggering events requiring recredentialing of the new owner. The process is rarely automatic and can take 30–90 days.

Common pitfalls:

• Late or incomplete notice leading to network termination.

• Retroactive denial of claims filled post-closing but pre-recredentialing approval.

• Denial based on the buyer’s compliance history at other locations.

Why it matters: A single major PBM can represent 70–90% of prescription revenue. Interrupted reimbursements create immediate cash-flow crises.

Recommended approach: Map all PBM contracts early, review change-of-control and recredentialing provisions, and submit applications as far in advance as permitted. Consider bridge financing or escrow arrangements to cover potential gaps.

Final Thoughts

Successful independent pharmacy transactions in 2026 will depend on disciplined attention to these regulatory and compliance details. Buyers who invest in thorough due diligence and careful structuring protect both their investment and ongoing operations. Sellers who address issues proactively can maximize value and facilitate smoother closings.

With the pace of consolidation expected to continue, early planning and experienced guidance are more valuable than ever.

At MDRXLaw, we regularly represent buyers and sellers in pharmacy acquisitions—from due diligence and contract negotiation to post-closing compliance and dispute resolution.

If you’re considering a pharmacy sale or acquisition, we invite you to contact our team for a confidential discussion. Reach us at (212) 668-0200, email info@mdrxlaw.com, or visit mdrxlaw.com.

We’re here to help you navigate the process confidently and close with peace of mind.